Stryker Co. (NYSE:SYK) Shares Sold by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC cut its holdings in Stryker Co. (NYSE:SYK) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 5,027 shares of the medical technology company’s stock after selling 140 shares during the period. Axxcess Wealth Management LLC’s holdings in Stryker were worth $1,816,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of SYK. Empowered Funds LLC increased its stake in shares of Stryker by 74.4% in the first quarter. Empowered Funds LLC now owns 6,938 shares of the medical technology company’s stock valued at $2,483,000 after purchasing an additional 2,960 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Stryker by 15.1% in the first quarter. Meeder Asset Management Inc. now owns 807 shares of the medical technology company’s stock valued at $289,000 after purchasing an additional 106 shares in the last quarter. Headlands Technologies LLC boosted its position in Stryker by 203.1% during the 1st quarter. Headlands Technologies LLC now owns 585 shares of the medical technology company’s stock worth $209,000 after acquiring an additional 392 shares during the period. Entropy Technologies LP purchased a new position in Stryker during the first quarter valued at approximately $4,170,000. Finally, William Allan Corp increased its stake in Stryker by 11.0% in the 1st quarter. William Allan Corp now owns 2,944 shares of the medical technology company’s stock valued at $1,054,000 after buying an additional 292 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Stryker news, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 67,381 shares of company stock worth $24,825,275. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

SYK has been the topic of a number of research reports. Stifel Nicolaus dropped their price target on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Morgan Stanley raised their price target on Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Needham & Company LLC boosted their price target on Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Robert W. Baird raised their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, Citigroup increased their price target on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Stock Performance

Shares of NYSE SYK opened at $378.86 on Tuesday. Stryker Co. has a 12 month low of $276.60 and a 12 month high of $381.54. The company has a market cap of $144.43 billion, a P/E ratio of 40.30, a P/E/G ratio of 2.83 and a beta of 0.91. The business’s 50 day moving average is $361.46 and its two-hundred day moving average is $345.77. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Stryker’s revenue was up 11.9% compared to the same quarter last year. On average, equities analysts expect that Stryker Co. will post 12.06 EPS for the current year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.